World Lung Cancer Vaccine Market Has Bright Potential, States Kuick Research in Topical Report Available at MarketPublishers.com

10 Jan 2017 • by Natalie Aster

LONDON – There are 3 lung cancer vaccines marketed today; 9 lung cancer vaccines are presently in advance Phase-II clinical trials, with 8 vaccines being in Phase-I/II trials.

To date, most lung cancer vaccines are in the experimental stage and remain stuck in clinical trials owing to which enormous unmet medical demands still need to be fulfilled. CureVac and Boehringer Ingelheim are engaged in the development of the vaccine, known as CV9202, to treat lung cancer which is at higher stage of clinical research. GlaxoSmithKline is currently developing a lung cancer vaccine called MAGE-A3 which is also under examination for other malignancies. Cell Genesys, Inc is developing GVAX for the treatment of lung cancer and a slew of clinical end points have been achieved in the process of investigation.

Once launched into the market at an early date, these drugs will likely generate considerable revenues over time due to increased levels of safety and efficacy, but till then this gap is set to be filled by other therapeutic agents. Furthermore, those lung cancer vaccines which are expected to make late market entry have to face competition with commercially available products giving them stiff competition. Hence, pharmacos have to introduce their products in market in the shortest possible time to grab major market shares worldwide.

Topical report “Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” elaborated by Kuick Research provides an in-depth analysis of the present-day clinical and non-clinical trends in the market on a global level. It examines the 30 lung cancer vaccines in clinical trials and offers comprehensive clinical insights into the different parameters related to the vaccines’ development.

The study examines the mechanism of cancer vaccines, overview of lung cancer proliferation, clinical trials of lung cancer vaccines, global incidence rate of lung cancer, overview of the global lung cancer vaccine market, need for personalized breast cancer vaccines, and deep insights into lung cancer vaccine clinical pipeline. The examination of the competitive landscape is also included.

More topical studies by Kuick Research are available at its page. 

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com